Jul 2 |
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
|
Jul 2 |
Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data
|
Jul 2 |
Cartesian Therapeutics Plummets On 'Watershed Moment' For CAR-T Drugs
|
Jul 2 |
Cartesian posts mid-stage win for lead asset; nabs $130M in financing
|
Jul 2 |
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
|
Jul 2 |
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
|
Jul 2 |
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
|
Jun 4 |
Oppenheimer starts Cartesian at outperform, cites lead drug potential
|
May 24 |
Mizuho starts Cartesian at buy, cites lead drug asset
|
May 22 |
Cartesian stock climbs 8% on FDA regenerative therapy designation
|